Despite research efforts and numerous ongoing clinical trials, there are only two FDA-approved adeno-associated virus (AAV) gene therapies available. Transitioning gene therapies from the laboratory bench to the clinic entails multiple considerations, including vector optimization, manufacturing, and safety. In this seminar, Dawn Bowles, Samira Kiani, David Schaffer, and Weidong Xiao will discuss the challenges of developing gene therapies and novel strategies to make AAV gene therapies safer and more effective.
Topics to be covered
- Gene therapies to improve cardiac transplant outcomes and minimize the need for immunosuppression
- New immunoregulatory strategies to address immune responses to gene therapies
- Enhancing viral gene delivery and manufacturing using directed evolution and genetic selection
- Understanding the risks associated with AAV genome integration
Thursday, June 29th, 2023 | 1:30 PM - 4:00 PM Eastern Time
This seminar will be available to view live and on demand.
Dawn Bowles, PhD
Samira Kiani, MD, PhD
University of Pittsburgh
David Schaffer, PhD
Hubbard Howe Jr. Distinguished Professor
University of California at Berkeley
Weidong Xiao, PhD